Analysis of Immune Responses in Mice Orally Immunized with Recombinant pMG36e-SP-TSOL18/ and pMG36e-TSOL18/ Vaccines of .

Cysticercosis is a cosmopolitan zoonotic parasitic disease infected by larval of (). Several drugs for the treatment of cysticercosis, such as praziquantel, albendazole, and mebendazole, have certain toxicity and side effects. Considering that there is no vaccine available, we studied a new vaccine for cysticercosis in this study. The complete gene and the optimized gene fragments were obtained using PCR-based accurate synthesis method. The secretory and intracellular recombinant pMG36e-SP-TSOL18/ () and pMG36e-TSOL18/ vaccines of were prepared. Immune responses in mice orally immunized with these two recombinant vaccines were analyzed by the determination of specific antibodies (IgG, IgG1, IgG2a, and sIgA) in serum, spleen lymphocyte proliferation, and cytokines (IL-2, IFN-, IL-4, and IL-10) in spleen lymphocyte culture supernatant. Our results showed that, after the first immunization, in these two recombinant vaccine groups, the levels of serum specific IgG, IgG2a, and IgG1 increased on 14-56 d and reached the highest level on days 42, 42, and 28, respectively. The level of specific sIgA of intestinal mucosa also increased on 14-56 d and reached the highest level on day 42. The level of spleen lymphocyte proliferation increased on 14-56 d and reached the highest level on day 42. The levels of IL-2, IFN-, IL-4, and IL-10 in spleen lymphocyte culture supernatant increased on 14-56 d and reached the highest level on days 42, 42, 28, and 28, respectively. These results indicated that the recombinant pMG36e-SP-TSOL18/ and pMG36e-TSOL18/ vaccines can induce specific cellular, humoral, and mucosal immune responses in mice with oral vaccination. More importantly, the recombinant pMG36e-SP-TSOL18/ vaccine has a better immune effect. In summary, these results demonstrated the possibility of using strain as a vector to deliver protective antigens of .